Literature DB >> 1694845

O-linked sugar chain of human granulocyte colony-stimulating factor protects it against polymerization and denaturation allowing it to retain its biological activity.

M Oh-eda1, M Hasegawa, K Hattori, H Kuboniwa, T Kojima, T Orita, K Tomonou, T Yamazaki, N Ochi.   

Abstract

Human granulocyte colony-stimulating factor (hG-CSF) is a glycoprotein carrying one O-linked sugar chain. To clarify the role of the oligosaccharide in hG-CSF, some biological and physicochemical properties of the deglycosylated hG-CSF and the intact factor were compared. Recombinant hG-CSF produced in transfected Chinese hamster ovary cells was sequentially digested with neuraminidase and endo-alpha-N-acetylgalactosaminidase. The deglycosylated hG-CSF was one-third as active as the intact form in the colony-forming assay, but it was almost as active as the intact hG-CSF in the cell proliferation assay using NFS-60 cells (NFS-60 bioassay). Inactivation of the deglycosylated hG-CSF was also found by NFS-60 bioassay after incubation for 2 days at pH values from 7 to 8 and at 37 degrees C. This inactivation was accompanied by polymerization of the factor which did not occur with the glycosylated factor. Circular dichroic and calorimetric analyses demonstrated that the deglycosylated hG-CSF is more sensitive to heat denaturation than the intact form and that the inactivation of both forms of hG-CSF was accompanied by conformational change of the proteins. From these results, it was concluded that the O-linked sugar chain of hG-CSF contributes to the stability of the factor by suppressing polymerization and/or its conformational changes.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1694845

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  34 in total

1.  Use of biosimilar filgrastim compared with lenograstim in autologous haematopoietic stem-cell transplant and in sibling allogeneic transplant.

Authors:  Shab Uddin; Pippa Russell; Maresa Farrell; Barbara Davy; Joe Taylor; Samir G Agrawal
Journal:  Ther Adv Hematol       Date:  2015-04

Review 2.  Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy.

Authors:  Ricardo J Solá; Kai Griebenow
Journal:  BioDrugs       Date:  2010-02-01       Impact factor: 5.807

3.  The structure of granulocyte-colony-stimulating factor and its relationship to other growth factors.

Authors:  C P Hill; T D Osslund; D Eisenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

Review 4.  Lenograstim: an update of its pharmacological properties and use in chemotherapy-induced neutropenia and related clinical settings.

Authors:  C J Dunn; K L Goa
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

Review 5.  Overview of the lenograstim pharmacoeconomics programme.

Authors:  G Oster; J Menzin; D Richard; V Cour-Chabernaud
Journal:  Pharmacoeconomics       Date:  1994       Impact factor: 4.981

6.  The kinetics of G-CSF folding.

Authors:  David N Brems
Journal:  Protein Sci       Date:  2002-10       Impact factor: 6.725

7.  Changes of immunoreactivity in alpha 1-antitrypsin in patients with autoimmune diseases.

Authors:  L Saso; B Silvestrini; R Lahita; C Y Cheng
Journal:  Inflammation       Date:  1993-06       Impact factor: 4.092

Review 8.  Lenograstim. A review of its pharmacological properties and therapeutic efficacy in neutropenia and related clinical settings.

Authors:  J E Frampton; Y E Yarker; K L Goa
Journal:  Drugs       Date:  1995-05       Impact factor: 9.546

Review 9.  Effects of glycosylation on the stability of protein pharmaceuticals.

Authors:  Ricardo J Solá; Kai Griebenow
Journal:  J Pharm Sci       Date:  2009-04       Impact factor: 3.534

10.  Abnormal glycosylation of alpha 2-macroglobulin, a non-acute-phase protein in patients with autoimmune diseases.

Authors:  L Saso; B Silvestrini; A Guglielmotti; R Lahita; C Y Cheng
Journal:  Inflammation       Date:  1993-08       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.